You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 18, 2024

NOVOLIN 70/30 Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Tradename: NOVOLIN 70/30
High Confidence Patents:2
Applicants:1
BLAs:1
Recent Clinical Trials: See clinical trials for NOVOLIN 70/30
Recent Clinical Trials for NOVOLIN 70/30

Identify potential brand extensions & biosimilar entrants

SponsorPhase
University of Illinois at ChicagoPhase 2
State University of New York - Downstate Medical CenterPhase 4
University of California, San FranciscoN/A

See all NOVOLIN 70/30 clinical trials

Pharmacology for NOVOLIN 70/30
Established Pharmacologic ClassInsulin
Chemical StructureInsulin
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for NOVOLIN 70/30 Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for NOVOLIN 70/30 Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Novo Nordisk Inc. NOVOLIN 70/30 insulin isophane human and insulin human Injection 019991 ⤷  Sign Up 2008-02-10 Company disclosures
Novo Nordisk Inc. NOVOLIN 70/30 insulin isophane human and insulin human Injection 019991 ⤷  Sign Up Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for NOVOLIN 70/30 Derived from Patent Text Search

These patents were obtained by searching patent claims

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.